Page 57 - GUÍA CLÍNICA HPN 2023

HPN GUÍA CLÍNICA
57
BIBLIOGRAFÍA
17. Sutherland DR, Illingworth A, Marinov I, et al. ICCS/ES-
CCA consensus guidelines to detect GPI-deficient cells
in paroxysmal nocturnal hemoglobinuria (PNH) and
related disorders part 2 - reagent selection and assay
optimization for high-sensitivity testing. Cytometry B
Clin Cytom. 2018;94(1):23-48. PMID: 29236353.
18. Illingworth A, Marinov I, Sutherland DR, et al. ICCS/ES-
CCA consensus guidelines to detect GPI-deficient cells
in paroxysmal nocturnal hemoglobinuria (PNH) and
related disorders part 3 - data analysis, reporting and
case studies. Cytometry B Clin Cytom. 2018;94(1):49-
66. PMID: 29236350.
19. Griffin M, Munir T. Management of thrombosis in par-
oxysmal nocturnal hemoglobinuria: a clinician’s guide.
Ther Adv Hematol. 2017;8(3):119-126. PMID: 28246555.
20. Lee JW, Jang JH, Kim JS, et al. Clinical signs and symp-
toms associated with increased risk for thrombosis in
patients with paroxysmal nocturnal hemoglobinuria
from a Korean Registry. Int J Hematol. 2013;97(6):749-
757. PMID: 23636668.
21. McNamara LA, Topaz N, Wang X, et al. High Risk for
Invasive Meningococcal Disease Among Patients Re-
ceiving Eculizumab (Soliris) Despite Receipt of Me-
ningococcal Vaccine. MMWR Morb Mortal Wkly Rep.
2017;66(27):734-737. PMID: 28704351.
22. Mbaeyi SA, Bozio CH, Duffy J, et al. Meningococcal
Vaccination: Recommendations of the Advisory Com-
mittee on Immunization Practices, United States, 2020.
MMWR Recomm Rep. 2020;69(9):1-41. PMID: 33417592.
23. Directiva Europea extensión indicación eculizumab
2015. Disponible en: http://www.ema.europa.eu/docs/
en_GB/document_library/EPAR_-_Assessment_Re-
port_-_Variation/human/000791/WC500186127.pdf.
24. Sheridan D, Yu ZX, Zhang Y, et al. Design and preclin-
ical characterization of ALXN1210: A novel anti-C5 an-
tibody with extended duration of action. PLoS One.
2018;13(4):e0195909. PMID: 29649283.